Affichage des résultats 1 à 6 sur 6 au total
-
Pré-publication, Document de travail
Jorge Vallejo Bustamante, Viet-Hung Nguyen, Liam Farrar, Kenji Watanabe, Takashi Taniguchi, et al.. Mapping the twist angle dependence of quasi-Brillouin zones in doubly aligned graphene/BN heterostructures. 2025. ⟨hal-05388053⟩
-
Thèse
Jorge Vallejo Bustamante. Singular orbital diamagnetism and paramagnetism in graphene. Condensed Matter [cond-mat]. Université Paris-Saclay, 2023. English. ⟨NNT : 2023UPASP024⟩. ⟨tel-04032004⟩
-
Article dans une revue
Emil Hagström, Philippe Gabriel Steg, Michael Szarek, Deepak Bhatt, Vera Bittner, et al.. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation, 2022, 146 (9), pp.657-672. ⟨10.1161/CIRCULATIONAHA.121.057807⟩. ⟨hal-04012895⟩
-
Article dans une revue
Gregory Schwartz, Michael Szarek, Vera Bittner, Rafael Diaz, Shaun Goodman, et al.. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. Journal of the American College of Cardiology, 2021, 78 (5), pp.421-433. ⟨10.1016/j.jacc.2021.04.102⟩. ⟨hal-03650902⟩
-
Article dans une revue
Mark Mcclanahan, Michael Dempsey, Helen Colhoun, Isabelle Zobouyan, Patrick Picault, et al.. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. Diabetes Care, 2021, 44 (5), pp.1219-1227. ⟨10.2337/dc20-2842⟩. ⟨hal-03672072⟩
-
Article dans une revue
Kausik Ray, Helen Colhoun, Michael Szarek, Marie Baccara-Dinet, Deepak Bhatt, et al.. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. The Lancet. Diabetes & Endocrinology , 2019, 7 (8), pp.618-628. ⟨10.1016/S2213-8587(19)30158-5⟩. ⟨hal-04012703⟩